IL6 and neuromyelitis optica: IL-6 clearly plays a significant role in NMO-SD as evidenced by increased IL-6 in CSF, serum and increases during times of disease activity; and positive clinical trials of anti-IL-6 receptor blockers but it is possible that IL-6 activity in seronegative NMO-SD may differ compared to seropositive disease.